Literature DB >> 7014876

The metabolism and pharmacology of D-penicillamine in man.

D Perrett.   

Abstract

D-penicillamine is rapidly absorbed from the intestine and appears in plasma as free penicillamine, cysteine-penicillamine disulfide, and penicillamine disulfide. Penicillamine binds firmly to serum and tissue proteins. The urinary excretion of S-methyl-D-penicillamine, cysteine-penicillamine disulfide, penicillamine disulfide, and a newly identified metabolite, homocysteine-penicillamine disulfide, has been quantitated for patients with rheumatoid arthritis, cystinuria, and Wilson's disease. Fifty percent of an oral dose is excreted in the feces, but the metabolites have not yet been fully characterized. The pharmacologic effects of D-penicillamine are associated with disulfide bond formation or cleavage, thiazolidine formation, and metal chelation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7014876

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  12 in total

Review 1.  A review and current perspective on Wilson disease.

Authors:  Mallikarjun Patil; Keyur A Sheth; Adarsh C Krishnamurthy; Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2013-07-06

Review 2.  Clinical pharmacokinetics of D-penicillamine.

Authors:  P Netter; B Bannwarth; P Péré; A Nicolas
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

3.  Free thiomalate levels in patients with rheumatoid arthritis treated with disodium aurothiomalate: relationship to clinical outcome of therapy.

Authors:  S R Rudge; D Perrett; A J Swannell
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

4.  D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis.

Authors:  Shuxi Qiao; Christopher M Cabello; Sarah D Lamore; Jessica L Lesson; Georg T Wondrak
Journal:  Apoptosis       Date:  2012-10       Impact factor: 4.677

5.  D-penicillamine and D-penicillamine-protein disulphide in plasma and synovial fluid of patients with rheumatoid arthritis.

Authors:  D A Joyce; R O Day
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

7.  Free thiomalate in plasma and urine of patients receiving sodium aurothiomalate.

Authors:  S R Rudge; D Perrett; A J Swannell
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

Review 8.  Penicillamine in rheumatoid arthritis. A problem of toxicity.

Authors:  H G Taylor; A Samanta
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

9.  D-penicillamine metabolism in an in-vivo model of inflamed synovium.

Authors:  D A Joyce; M J Forrest; P M Brooks
Journal:  Agents Actions       Date:  1988-12

Review 10.  Disease-modifying antirheumatic drugs. Potential effects in older patients.

Authors:  G Gardner; D E Furst
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.